Nivolunix

40 mg

100 mg

• Generic Name: Nivolumab

• Form: Sterile intravenous injection

• Strengths Available:

  • Nivolunix 40: 40 mg per 4 mL vial (10 mg/mL)

  • Nivolunix 100: 100 mg per 10 mL vial (10 mg/mL) 

• Packaging: Single-vial presentation, suitable for controlled dosing

---

🔬 Mechanism of Action

Nivolumab acts as a PD‑1 immune checkpoint inhibitor. By blocking PD‑1’s interaction with its ligands (PD‑L1/PD‑L2), Nivolunix restores T-cell activity, enabling the immune system to recognize and destroy cancer cells 

---

🎯 Approved & Emerging Indications

Healthcare providers use Nivolunix for a range of malignancies, including:

• Non‑Small Cell Lung Cancer (NSCLC)

• Melanoma

• Head & Neck Cancer

• Hodgkin Lymphoma

• Hepatocellular Carcinoma (HCC)

• Additional studies and case reports also highlight its use in renal cell carcinoma, esophageal cancer, urothelial cancer, colorectal cancer, gastric/gastroesophageal junction cancer, and malignant pleural mesothelioma 

---

📈 Clinical Data & Use

• Used as a slow IV infusion, typically administered every 2–4 weeks.

• Often used alone or in combination (e.g., with ipilimumab) to increase effectiveness in advanced tumors 

• A recent case report documented a complete response in esophageal cancer after concurrent chemoradiotherapy followed by adjuvant Nivolunix 

---

🧊 Handling & Pharmacology

• Storage: Refrigerate at 2–8 °C, protect from light; do not freeze or shake 

• Pharmacokinetics: Doses range from 0.1 to 20 mg/kg, administered as a 60-minute infusion every 2–3 weeks. Clearance decreases over time, reflecting immune modulation 

---

⚠️ Safety & Monitoring

• Common adverse events include infusion reactions (fever, chills, rash), and immune-related toxicities affecting lungs, liver, skin, thyroid, or gastrointestinal tract .

• Patients are monitored during infusion, and standard protocols are in place to manage side effects .